After some pharmacies and hospitals reported running out of Moderna's omicron-targeted booster, the FDA authorized five lots of the product made at the drugmaker's Bloomington, Ind., facility, which isn't authorized to manufacture the modified vaccine. 

With COVID-19 vaccine-makers pivoting production as the virus mutates, Jim Cafone, Pfizer's senior vice president of global supply chain, said it is time for pharmaceutical companies to redevelop their logistic strategies, The Wall Street Journal reported Sept. 24.

In a recent white paper from Becker’s Supply Chain Leadership Virtual Forum, titled “Health system leaders weigh in on supply chain transformation,” 6 healthcare supply chain leaders representing Cardinal Health, Mayo Clinic, UChicago Medicine and other healthcare institutions discussed how supply chains can become a strategic asset when bolstered by the power of data, standardization, and process efficiency.

Workforce shortages and managing supply chain disruptions as the COVID-19 pandemic eases in severity are top of mind for hospital supply leaders. 

Reauthorizing the FDA's user fee program, which allows the agency to decide how much to charge pharmaceutical and medical device-maker companies for their product submissions,  was added to a spending bill Sept. 22 to prevent a government shutdown, according to The Hill.

The FDA is loosening requirements surrounding the distribution of naloxone to increase Americans' access to the opioid overdose antidote.

Here are 10 health systems and hospitals that posted job listings seeking supply chain expertise in the last week. 

From an unusual number of submissions of low-quality COVID-19 tests to limits at U.S. laboratories, the FDA faced multiple barriers in the early days of the COVID-19 pandemic, an HHS report found. 

From a potential cybersecurity risk for some insulin pumps to health equity issues with pulse oximeters, here are four medical device updates the FDA has published as of Sept. 15: 

Drug and medical devicemakers with operations in Puerto Rico are cautiously optimistic that Hurricane Fiona will cause few ripples across the medical supply chain.

When health systems and public health departments were scrambling to respond to the COVID-19 pandemic in early 2020, New York bought ventilators and X-ray machines for more than a quarter of a billion dollars. The products were never used and are sitting in storage, according to a Sept. 20 Politico report. 

Pharmacies and hospitals across the country are running out of Moderna's tweaked vaccine booster, but the vaccine-maker said it expects supply to return to normal levels in a few days. 

Houston-based Texas Medical Center on Sept. 20 unveiled plans to build a biomanufacturing center called the TMC BioPort. It will focus on manufacturing and distributing medical supplies, therapies and pharmaceuticals. 

The FDA cleared the first pediatric insertable cardiac system for approval Sept. 20. 

Pharmaceutical company GSK launched a sustainable procurement program Sept. 20 in its efforts to reach net-zero impact on the climate. A big chunk of GSK's carbon emissions, 40 percent, comes from its supply chain, the company said in a news release. 

Medical device company Mölnlycke has opened a $49.8 million factory in Malaysia to increase production of surgical gloves. 

A growing list of drugmakers are reporting back orders for Adderall and its generics in a shortage that's been slowly worsening since August. 

As the U.S. works to attract biomanufacturing power within its borders, some Asian countries have largely escaped global supply chain issues, Bloomberg columnist Anjani Trivedi wrote in a Sept. 18 opinion.

As patient consumerization continues to drive forward and healthcare adjusts to a evolving pandemic environment, hospital leaders are tasked with finding new ways of maintaining a competitive edge.

Two weeks after the CDC and FDA authorized Moderna's bivalent omicron booster for emergency use, doses are running out in a few U.S. states.